Cell3™ Preserver Whole blood stabilization tube
Cell3™ Preserver Whole blood stabilization tube
Cell3™ Xtract: Cell-free DNA extraction kit
Cell3™ Xtract: Cell-free DNA extraction kit
Cell3™ Target: Custom panel for cfDNA
Cell3™ Target: Custom panel for cfDNA
GALEAS™ Hereditary Plus
GALEAS™ Hereditary Plus
GALEAS™ Tumor
GALEAS™ Tumor
Bead Xtract cfDNA kit
Bead Xtract cfDNA kit
GALEAS™ Bladder
GALEAS™ Bladder
Cell3™ Target: Nexome
Cell3™ Target: Nexome
previous arrow
next arrow
Cell3™ Preserver Whole blood stabilization tube
Cell3™ Xtract: Cell-free DNA extraction kit
Cell3™ Target: Custom panel for cfDNA
GALEAS™ Hereditary Plus
GALEAS™ Tumor
Bead Xtract cfDNA kit
GALEAS™ Bladder
Cell3™ Target: Nexome
previous arrow
next arrow

News

Our Products

The future of genomic medicine continues to evolve.

We support detection, monitoring, and treatment decision-making through clinically validated end-to-end workflows.

GALEAS™ Oncology Panels

This comprehensive solution for tissue and liquid biopsies combines the GALEAS™ Target NGS technology-based target panel with our proprietary analysis pipeline. It enables early and accurate cancer detection. Designed to detect low-frequency mutations, it supports precise patient monitoring and informed treatment decision-making in cancer research and clinical practice.

Cell3™ Target: Custom Panel

Cell3™ Target is a high-precision NGS target panel validated in various types of DNA samples, including cfDNA, gDNA, and FFPE DNA.

To ensure uniform coverage, we implement strict quality control (QC) measures and utilize error suppression technology, enabling accurate detection of minor variants down to an allele frequency (VAF) of 0.1%.

With our free panel design tool, you can easily and quickly create custom panels, targeting anywhere from 1 to 1,000 genes based on information such as BED files, gene lists, and specific genomic coordinates. Cell3™ Target features industry-leading integrated algorithms that automatically mask repetitive regions and fill design gaps, ensuring efficient and uniform coverage of target areas.

Germline

The NGS target panel designed using Cell3™ Target technology accurately detects chromosomal abnormalities, including SNVs, indels, and CNVs.

Traditional methods for assessing germline variants often require multiple tests, such as FISH, karyotyping, MLPA, and microarray. Our NGS-based solution integrates these workflows, allowing for the analysis of SNVs, indels, and CNVs in a single assay, significantly saving time and resources.

cfDNA Analysis Solutions

In genomic medicine, proper sample preparation is crucial for obtaining accurate results. This is especially important when handling low quantities of cfDNA, where preventing contamination from gDNA is essential.

Nonacus believes that maximizing the yield, purity, and quality of cfDNA is key to reliable analysis. To address challenges at each step, we offer highly designed products, including Cell3™ Preserver for optimizing whole blood collection and Cell3 Xtract and Bead Xtract specifically for cfDNA extraction.

By using these collection tubes and advanced sample preparation kits, you can enhance the sensitivity and accuracy of subsequent genetic analyses, unlocking the full potential of cfDNA. This enables precise and insightful genomic analysis, supporting more accurate diagnoses and research.

GALEAS™ uPCR: Precision in Detection

Ultra-PCR (uPCR) is an advanced amplification method that enhances the sensitivity and specificity of mutation detection, particularly in low-frequency variants found in cell-free DNA (cfDNA). This technology provides accurate and reliable results, making it ideal for precision oncology.

GALEAS™ uPCR: ESR1 employs Nonacus’ proprietary uPCR technology to detect 11 critical ESR1 mutations linked to endocrine therapy resistance in breast cancer. With its simple, streamlined protocol, GALEAS™ uPCR: ESR1 is a fast, cost-effective solution that requires no sophisticated equipment, providing accurate results in under three hours.

This assay empowers clinical and research laboratories with the ability to detect ESR1 mutations quickly and efficiently, supporting informed decisions in metastatic breast cancer management.